CA3112188A1 - Paclitaxel-hyaluronic acid conjugate in the treatment of non-muscle invasive bladder cancer - Google Patents
Paclitaxel-hyaluronic acid conjugate in the treatment of non-muscle invasive bladder cancer Download PDFInfo
- Publication number
- CA3112188A1 CA3112188A1 CA3112188A CA3112188A CA3112188A1 CA 3112188 A1 CA3112188 A1 CA 3112188A1 CA 3112188 A CA3112188 A CA 3112188A CA 3112188 A CA3112188 A CA 3112188A CA 3112188 A1 CA3112188 A1 CA 3112188A1
- Authority
- CA
- Canada
- Prior art keywords
- paclitaxel
- treatment
- pharmaceutical composition
- prodrug
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Materials Engineering (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102018000009731 | 2018-10-25 | ||
| IT102018000009731A IT201800009731A1 (it) | 2018-10-25 | 2018-10-25 | Coniugato paclitaxel - acido ialuronico nel trattamento del carcinoma vescicale non infiltrante |
| PCT/IB2019/059073 WO2020084525A1 (en) | 2018-10-25 | 2019-10-23 | Paclitaxel-hyaluronic acid conjugate in the treatment of non-muscle invasive bladder cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3112188A1 true CA3112188A1 (en) | 2020-04-30 |
Family
ID=65324453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3112188A Pending CA3112188A1 (en) | 2018-10-25 | 2019-10-23 | Paclitaxel-hyaluronic acid conjugate in the treatment of non-muscle invasive bladder cancer |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US20200397909A1 (https=) |
| EP (1) | EP3870233B1 (https=) |
| JP (1) | JP7518815B2 (https=) |
| KR (1) | KR102913965B1 (https=) |
| CN (2) | CN112805035A (https=) |
| CA (1) | CA3112188A1 (https=) |
| DK (1) | DK3870233T3 (https=) |
| EA (1) | EA202190614A1 (https=) |
| ES (1) | ES2971217T3 (https=) |
| FI (1) | FI3870233T3 (https=) |
| HR (1) | HRP20240188T1 (https=) |
| HU (1) | HUE066288T2 (https=) |
| IT (1) | IT201800009731A1 (https=) |
| LT (1) | LT3870233T (https=) |
| MA (1) | MA63879B1 (https=) |
| PL (1) | PL3870233T3 (https=) |
| PT (1) | PT3870233T (https=) |
| RS (1) | RS65193B1 (https=) |
| SI (1) | SI3870233T1 (https=) |
| SM (1) | SMT202400021T1 (https=) |
| WO (1) | WO2020084525A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT202000007747A1 (it) * | 2020-04-10 | 2021-10-10 | Fidia Farm Spa | Coniugato acido ialuronico-paclitaxel nel trattamento del mesotelioma |
| IT202000008209A1 (it) * | 2020-04-17 | 2021-10-17 | Fidia Farm Spa | Procedimento di sintesi di un coniugato acido ialuronico-paclitaxel |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0138572B1 (en) | 1983-10-11 | 1990-07-25 | FIDIA S.p.A. | Hyaluronic acid fractions having pharmaceutical activity, methods for preparation thereof, and pharmaceutical compositions containing the same |
| IT1263393B (it) | 1993-07-30 | 1996-08-05 | Fidia Advanced Biopolymers Srl | Processo per la preparazione e purificazione di acido ialuronico ad alto peso molecolare |
| NZ516873A (en) | 2001-02-12 | 2003-11-28 | Warner Lambert Co | Compositions containing retinoids and erb inhibitors and their use in inhibiting retinoid skin damage |
| ITPD20020271A1 (it) | 2002-10-18 | 2004-04-19 | Fidia Farmaceutici | Composti chimico-farmaceutici costituiti da derivati dei taxani legati covalentemente all'acido ialuronico o ai suoi derivati. |
| AR047938A1 (es) * | 2003-08-25 | 2006-03-15 | Combinatorx Inc | Formulaciones, conjugados y combinaciones de farmacos para el tratamiento de neoplasmas |
| ITMI20071267A1 (it) | 2007-06-22 | 2008-12-23 | Fidia Farmaceutici | Uso di coniugati dell'acido ialuronico nel trattamento locale di malattie cutanee iperproliferative |
| IT1402384B1 (it) | 2010-09-09 | 2013-09-04 | Fidia Farmaceutici | Processo per la produzione di acido ialuronico in escherichia coli o bacillus megaterium |
| IT1402385B1 (it) | 2010-09-09 | 2013-09-04 | Fidia Farmaceutici | Processo per la produzione di acido ialuronico in escherichia coli o bacillus subtilis |
| EP3290511B1 (en) | 2011-11-09 | 2020-08-26 | Spinalcyte, LLC | Dermal fibroblasts for treatment of degenerative disc disease |
| IT201600079633A1 (it) | 2016-07-28 | 2018-01-28 | Fidia Farm Spa | Procedimento di preparazione e purificazione del sale sodico dell’acido ialuronico |
| CN110859962B (zh) | 2019-11-25 | 2021-01-22 | 山东大学 | 巴比妥酸衍生物修饰的二硫化钼二维纳米材料及其应用 |
-
2018
- 2018-10-25 IT IT102018000009731A patent/IT201800009731A1/it unknown
-
2019
- 2019-10-23 CA CA3112188A patent/CA3112188A1/en active Pending
- 2019-10-23 PT PT198016305T patent/PT3870233T/pt unknown
- 2019-10-23 ES ES19801630T patent/ES2971217T3/es active Active
- 2019-10-23 LT LTEPPCT/IB2019/059073T patent/LT3870233T/lt unknown
- 2019-10-23 WO PCT/IB2019/059073 patent/WO2020084525A1/en not_active Ceased
- 2019-10-23 FI FIEP19801630.5T patent/FI3870233T3/fi active
- 2019-10-23 EA EA202190614A patent/EA202190614A1/ru unknown
- 2019-10-23 PL PL19801630.5T patent/PL3870233T3/pl unknown
- 2019-10-23 HR HRP20240188TT patent/HRP20240188T1/hr unknown
- 2019-10-23 JP JP2021515655A patent/JP7518815B2/ja active Active
- 2019-10-23 KR KR1020217007729A patent/KR102913965B1/ko active Active
- 2019-10-23 RS RS20240122A patent/RS65193B1/sr unknown
- 2019-10-23 SI SI201831054T patent/SI3870233T1/sl unknown
- 2019-10-23 MA MA63879A patent/MA63879B1/fr unknown
- 2019-10-23 CN CN201980064603.9A patent/CN112805035A/zh active Pending
- 2019-10-23 US US16/959,979 patent/US20200397909A1/en not_active Abandoned
- 2019-10-23 DK DK19801630.5T patent/DK3870233T3/da active
- 2019-10-23 CN CN202510138513.7A patent/CN119792555A/zh active Pending
- 2019-10-23 HU HUE19801630A patent/HUE066288T2/hu unknown
- 2019-10-23 EP EP19801630.5A patent/EP3870233B1/en active Active
- 2019-10-23 SM SM20240021T patent/SMT202400021T1/it unknown
-
2021
- 2021-03-17 US US17/204,183 patent/US20210196833A1/en not_active Abandoned
- 2021-05-10 US US17/315,962 patent/US12465649B2/en active Active
-
2023
- 2023-12-14 US US18/539,827 patent/US20240123077A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN119792555A (zh) | 2025-04-11 |
| SI3870233T1 (sl) | 2024-03-29 |
| US20210268119A1 (en) | 2021-09-02 |
| EP3870233A1 (en) | 2021-09-01 |
| PL3870233T3 (pl) | 2024-05-06 |
| EA202190614A1 (ru) | 2021-06-03 |
| DK3870233T3 (da) | 2024-02-05 |
| US20200397909A1 (en) | 2020-12-24 |
| US12465649B2 (en) | 2025-11-11 |
| ES2971217T3 (es) | 2024-06-04 |
| SMT202400021T1 (it) | 2024-03-13 |
| KR102913965B1 (ko) | 2026-01-16 |
| JP2022503771A (ja) | 2022-01-12 |
| CN112805035A (zh) | 2021-05-14 |
| FI3870233T3 (fi) | 2024-02-07 |
| JP7518815B2 (ja) | 2024-07-18 |
| KR20210083249A (ko) | 2021-07-06 |
| RS65193B1 (sr) | 2024-03-29 |
| HRP20240188T1 (hr) | 2024-05-10 |
| US20210196833A1 (en) | 2021-07-01 |
| EP3870233B1 (en) | 2023-12-06 |
| IT201800009731A1 (it) | 2020-04-25 |
| PT3870233T (pt) | 2024-02-01 |
| MA63879B1 (fr) | 2024-02-29 |
| LT3870233T (lt) | 2024-02-26 |
| US20240123077A1 (en) | 2024-04-18 |
| WO2020084525A1 (en) | 2020-04-30 |
| HUE066288T2 (hu) | 2024-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2045270B1 (en) | Taxanes covalently bound to hyaluronic acid | |
| EP0662002B1 (en) | Alginate-bioactive agent conjugates | |
| US20240123077A1 (en) | Paclitaxel-hyaluronic acid conjugate in the treatment of non-muscle invasive bladder cancer | |
| US9962469B2 (en) | Adhesion-preventing preparation comprising composition comprising polycationic triblock copolymer and polyanionic polymer | |
| WO2019210414A1 (en) | Fucan-based compounds and complexes | |
| CN115667214A (zh) | 包括药物二聚体的纳米颗粒及其用途 | |
| CN106692179B (zh) | 关节腔注射用含低分子量黄原胶的药物制剂及其制备方法 | |
| HK40048954B (en) | Paclitaxel-hyaluronic acid conjugate in the treatment of non-muscle invasive bladder cancer | |
| HK40048954A (en) | Paclitaxel-hyaluronic acid conjugate in the treatment of non-muscle invasive bladder cancer | |
| KR102162774B1 (ko) | 커큐민 유도체 함유 pH 민감성 블록 공중합체를 유효성분으로 포함하는 염증성 질환의 예방, 개선 또는 치료용 조성물 | |
| US7476659B2 (en) | Liquid composition for bulging mucous membrane for use in endoscopic surgery comprising a chitosan derivative containing carbohydrate chains | |
| EA043782B1 (ru) | Конъюгат паклитаксела и гиалуроновой кислоты в лечении мышечно-неинвазивного рака мочевого пузыря | |
| Mangla et al. | Hyaluronic acid: the ingenious molecule | |
| EP3142749B1 (en) | Viscosupplement composition comprising ulvan for treating arthritis | |
| Zhu | Nanoparticles Targeting Tumour Associated Macrophages | |
| CN121891549A (zh) | 一种基于紫杉醇衍生物的组合物及其制备方法和应用 | |
| CN115515640A (zh) | 用于治疗间皮瘤的ha-紫杉醇缀合物 | |
| HK1082753B (en) | Taxanes covalently bound to hyaluronic acid or hyaluronic acid derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20240910 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20240910 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241018 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241018 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241018 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241204 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250415 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250430 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251017 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251017 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20251023 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20260126 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260204 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260204 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260204 |